TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: radiation pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: radiation esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Index of affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Index of psychomotoricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse events (AEs), Serious Adverse Events (SAEs), and Unanticipated Device Effects (UDEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cannabis Use Relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Cannabis Use Days Per Week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative Percentage of the Administered Dose of [14C]CCX168 Recovered in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Percentage of the Administered Dose of [14C]CCX168 Recovered in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 26 in the Friedreich's Ataxia Rating Scale (FARS)-mNeuro Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure 88 (GMFM 88) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley Scales of Infant Development III Gross Motor Skill Domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-Cycle Induction Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-cycle Induction Peripheral Neuropathy (PN) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3-4 Induction Peripheral Neuropathy Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Evolution of immune blood populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systolic Ejection Fraction as a Measure of Left Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Worsened Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adherence to post-discharge recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in magnitude of Bold signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB treatment completion rates in prison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB treatment completion rates after release from prison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recipients with >50% donor T cell chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft-failure free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in spirometry (FEV1, FVC, FEV1/FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in 6 Minute Walk Distance (6 MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in St George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Test Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival outcomes from QPOP-directed treatment regimens
Endpoint domain: Mortality/survival
Primary endpoint: Reaction time to respond to visual stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hormone measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweat duct density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-noise ratio benefit for speech in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strength of golf swing measured by carry distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Unintentional excision rate of parathyroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in dietary habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cognitive Assessment Using MoCA Version 7.1 Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Colony Forming Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve of c-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: grade of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in bone mineral content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in total bone mineral density (BMD)-z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Action Research Arm Test (ARAT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of reslizumab therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of early stage bladder cancer
Endpoint domain: Mortality/survival
Primary endpoint: Progression of early stage bladder cancer
Endpoint domain: Mortality/survival
Primary endpoint: Sexual and protective behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in left ventricular outflow tract velocity time integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: time-to-improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the active phase of the first stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of individuals planning lung cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Size of tumor foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional Ambulatory Categories
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF3B1 status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Incidence of ADA
Endpoint domain: Adverse events/effects
Primary endpoint: redisplacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Can Safely Tolerate and Complete Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Allograft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory/immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distance from the ureter to the uterine vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance from the ureter to the right gonadal vessel at the pelvic sidewall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance from the ureter to the left gonadal vessel at the pelvic sidewall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance from the ureter to the right gonadal vessel where the gonadal vessel enters into the ovary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of asymptomatic episodes of paroxysmal atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Overall Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Visual Analog Scale Item
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity and Specificity of the Natriuretic Peptide Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body dysmorphic disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: canine retraction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of phosphorylation in mucosal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of drug in mucosal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PWTT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive Campylobacter detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in radiation metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Exercise Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: composite outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erosive wear assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Epistaxis Severity Score (ESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal aerobic exercise capacity (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone resorption (Dpyr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbar spine bone mineral density (BMD) via dual energy e-ray absorptiometry (DXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes of sublingual microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of papules and pustules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Tobacco Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Gambling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Post-Traumatic Stress Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Depression Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Anxiety Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rating of line severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of buprenorphine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Red Blood Cells Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measure
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Psychometric Hepatic Encephalopathy Score (PHES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First Relapse of Takayasu Arteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of inactivated influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and Tolerability (Number of Participants with Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate Clinical and Parasitological Response (ACPR) on Days 28 and 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 Peak Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional status as assessed by Vulnerable Elders Survey-13
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional status as assessed by Instrumental Activity of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional status as assessed by Activity of Daily Living Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mood deterioration incidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive functions as assessed by the Mini Mental State Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive functions as assessed by Clock Drawing Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy and Reaction time to visual target direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle error between stick orientation and real vertical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway path and surface area of center of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood arsenic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amplitude of the CNV (Contingent Negative Variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle Cross-Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Milligram Equivalents Taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: weight-adjusted cumulative morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failure leading to patient death or retransplantation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Hand/Foot Syndrome (HFS) > Grade 1
Endpoint domain: Adverse events/effects
Primary endpoint: Amino acid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentric hamstrings/quadriceps ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in urine albumin to creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Peritraumatic Distress Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain subscale of the Endometriosis Health Profile (EHP-30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily time physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NCI CTCAE grade > 3 infusional toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of transfusion associated graft versus host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of treatment related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Long term performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Arthritis Hand Function Test (AHFT)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived Hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Desire to Eat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Prospective Food Consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: readmission or hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Development of histologically proven acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Acute genito-urinary and gastrointestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants receiving protocol treatment until cycle 6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes of CD8+ tumor infiltrating immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall confirmed hematologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with etiologic diagnosis established
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Watertight Dural Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early Clinical Response Rate (ECRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fifth or Sixth AMA Guide impairment rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability Questionnaire Mean Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve of the Empagliflozin in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Metformin in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Linagliptin in Plasma (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Linagliptin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak delivery time for CPT11 tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until failure of the strategy
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Time (OS) after chemoembolization
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Time (OS) after radioembolization
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Time (OS) after pharmaceutical treatment
Endpoint domain: Mortality/survival
Primary endpoint: Peripheral airway resistance (from 4th bifurcation on)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total airway volume for the segmented airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total airway resistance for the segmented airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of giant cell arteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural signals related to stopping and conflicting movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of Uptake of 18F-VM4-037
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events following infusion of NK and NKT cells
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving and Maintaining HbA1c Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best-corrected Visual Acuity (LogMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Retinal Thickness (micron)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subfoveal Choroidal Thickness (micron)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of ELISA confirmed rotavirus severe gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes